[Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19].
Recommandations CCAFU sur la prise en charge des cancers de l’appareil urogénital en période d’épidémie au Coronavirus COVID-19.
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Decision Making
Disease Management
Epidemics
Humans
Infection Control
Infectious Disease Transmission, Patient-to-Professional
/ prevention & control
Male
Pandemics
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Societies, Medical
Urogenital Neoplasms
/ surgery
Urologists
Bladder cancer
COVID-19
Cancer de la prostate
Cancer de la vessie
Cancer du penis
Cancer du rein
Cancer du testicule
Kidney cancer
Penile cancer
Prostate cancer
Testicular cancer
Journal
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
25
03
2020
revised:
25
03
2020
accepted:
25
03
2020
pubmed:
1
4
2020
medline:
8
5
2020
entrez:
1
4
2020
Statut:
ppublish
Résumé
The French population is facing the COVID-19 pandemic and the health system have been reoriented in emergency for the care of patients with coronavirus. The management of cancers of the urinary and male genital tracts must be adapted to this context. An expert opinion documented by a literature review was formulated by the Cancerology Committee of the French Association of Urology (CCAFU). The medical and surgical management of patients with any cancers of the urinary and male genital tracts must be adapted by modifying the consultation methods, by prioritizing interventions according to the intrinsic prognosis of cancers, taking into account the patient's comorbidities. The protection of urologists from COVID-19 must be considered. The CCAFU issues an expert opinion on the measure to be taken to adapt the management of cancers of the male urinary and genital tract to the context of pandemic by COVID-19.
Identifiants
pubmed: 32224294
pii: S1166-7087(20)30102-0
doi: 10.1016/j.purol.2020.03.009
pmc: PMC7146722
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Langues
fre
Sous-ensembles de citation
IM
Pagination
221-231Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Références
World J Surg Oncol. 2016 Apr 27;14:124
pubmed: 27121955
J Urol. 2017 Dec;198(6):1346-1352
pubmed: 28652123
World J Urol. 2018 Oct;36(10):1643-1649
pubmed: 29730837
Prog Urol. 2018 Nov;28 Suppl 1:R81-R132
pubmed: 31610875
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
Eur Urol. 2015 Nov;68(5):805-11
pubmed: 25800944
World J Urol. 2014 Apr;32(2):475-9
pubmed: 23455886
J Urol. 1990 Mar;143(3):520-3
pubmed: 2304163
Eur Urol Oncol. 2019 Jul;2(4):390-396
pubmed: 31277775
Prog Urol. 2018 Nov;28 Suppl 1:R34-R47
pubmed: 31610873
BJU Int. 2018 Jul;122(1):89-98
pubmed: 29569824
Eur Urol. 2018 Aug;74(2):157-164
pubmed: 29625756
JAMA. 2020 Mar 11;:
pubmed: 32159775
Nat Rev Urol. 2014 Dec;11(12):702-11
pubmed: 25403241
Prog Urol. 2012 Dec;22(16):989-98
pubmed: 23178094
Arch Esp Urol. 2012 Jun;65(5):542-9
pubmed: 22732780
Prog Urol. 2019 Sep 20;28(S1):R48-R80
pubmed: 32093463
Eur Urol. 2020 Jun;77(6):713-724
pubmed: 32089359
JAMA Oncol. 2019 Feb 1;5(2):164-170
pubmed: 30543350
Cancer. 2002 Jul 15;95(2):281-6
pubmed: 12124827
Eur Urol. 2015 Sep;68(3):408-15
pubmed: 25698065
J R Army Med Corps. 1985 Oct;131(3):140-1
pubmed: 4087240
J Urol. 2014 Sep;192(3):659-64
pubmed: 24641909
Eur Urol. 2016 Aug;70(2):265-80
pubmed: 26707869